Rigel Pharmaceuticals RIGL Operating Lease Liabilities (Current)
Operating Lease Liabilities (Current) at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.
The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rigel Pharmaceuticals's operating lease liabilities (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rigel Pharmaceuticals's operating lease liabilities (current)?
- Rigel Pharmaceuticals (RIGL) reported operating lease liabilities (current) of $636K in Q1 2026.
- How has Rigel Pharmaceuticals's operating lease liabilities (current) changed year-over-year?
- Rigel Pharmaceuticals's operating lease liabilities (current) increased by 39.5% year-over-year, from $456K to $636K.
- What is the long-term trend for Rigel Pharmaceuticals's operating lease liabilities (current)?
- Over 5 years (2020 to 2025), Rigel Pharmaceuticals's operating lease liabilities (current) has grown at a -41.0% compound annual growth rate (CAGR), from $8.62M to $614K.
- What does operating lease liabilities (current) mean?
- The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.